UGT1A1 Fragment Analysis: Genotyping the ( TA ) n Variable Repeat Polymorphism for Clinical Applications

Ryan N. Baugher; Kristen Pike; Teri M. Plona; Stephanie D. Mellott; Todd B. Young; Heidi E. Lawhorn; Stephen M. Hewitt

doi:10.1002/jcla.70214

March 29, 2026Journal of Clinical Laboratory AnalysisOpen Access

UGT1A1 Fragment Analysis: Genotyping the ( TA ) n Variable Repeat Polymorphism for Clinical Applications

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research focuses on analyzing the UGT1A1 gene polymorphism to enhance clinical pharmacogenomic applications.
Conducted fragment analysis of UGT1A1 gene
Included genotyping of the (TA)n variable repeat polymorphism
Evaluated the assay's effectiveness in clinical settings
Achieved a correction rate of 7.8% in patient sample genotyping
2.77% of miscalls were attributed to the UGT1A1*37 variant

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical implementation shows 7.8% correction rate in genotyping, suggesting improved accuracy in pharmacogenomics.

Abstract

Clinical implementation as a supplemental assay to other pharmacogenomics offerings resulted in a correction rate of the loci within patient samples of 7.8%, with 2.77% caused by miscalling UGT1A1*37 variant.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Baugher et al. (2026) studied this question.

synapsesocial.com/papers/69ccb76c16edfba7beb8953c https://doi.org/10.1002/jcla.70214

View Full Paper

Ask AI

Bookmark

Share

UGT1A1 Fragment Analysis: Genotyping the ( TA ) n Variable Repeat Polymorphism for Clinical Applications

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

UGT1A1 Fragment Analysis: Genotyping the ( TA ) n Variable Repeat Polymorphism for Clinical Applications

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading